当前位置: 首页 >> 检索结果
1. FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis.
作者: Masaru Sasaki.;Joshua X Wang.;Ryugo Teranishi.;Takefumi Itami.;Yusen Zhou.;Kanak V Kennedy.;Ann Semeao.;Satoshi Ishikawa.;Takeo Hara.;Emily A McMillan.;Mark Mahon.;Hailey Golden.;Diya Dhakal.;Alyssa Baccarella.;Heidi Winters.;Chizoba N Umeweni.;Benjamin J Wilkins.;Tatiana A Karakasheva.;Kelly A Whelan.;Sydney M Shaffer.;Melanie A Ruffner.;Amanda B Muir.
来源: Gut. 2025年
Eosinophilic oesophagitis (EoE) is a chronic allergic disease characterised by oesophageal epithelial remodelling, barrier dysfunction and inflammation. The transcription factor forkhead box M1 (FOXM1) has been shown to be a key regulator of epithelial proliferation and inflammation in allergic asthma.
2. Acute upper gastrointestinal bleeding in the UK: 2022 audit update.
作者: Gaurav B Nigam.;Kathryn Oakland.;Sarah Hearnshaw.;John Grasnt-Casey.;Paul Davies.;Paula Dhiman.;Shane W Goodwin.;Bhaskar Kumar.;Elizabeth Ratcliffe.;Joanna A Leithead.;Raman Uberoi.;Lise Estcourt.;Vipul Jairath.;Simon P L Travis.;Mike F Murphy.;Adrian Stanley.;Andrew Douds.; .
来源: Gut. 2025年
Acute upper gastrointestinal bleeding (AUGIB) is a common medical emergency with evolving demographics and management strategies, particularly in medical/endoscopic therapy and transfusion strategies.
3. Intestinal blood vessel-associated macrophages and gut-vascular barrier dysfunction in cirrhosis.
作者: Lena Smets.;Maria Francesca Viola.;Markus Boesch.;Jana Raman.;Lukas Van Melkebeke.;Max Nobis.;Emilio Flint.;Nika Pajk.;Paola Brescia.;Alessandra Silvestri.;Rita Feio-Azevedo.;Elodie Modave.;Lander De Herdt.;Annalisa Sanga.;Oltin Tiberiu Pop.;Olivier Govaere.;Jef Verbeek.;Alexandre Denadai-Souza.;David Cassiman.;Niels Vandamme.;Bram Boeckx.;Diether Lambrechts.;Maria Rescigno.;Christine Bernsmeier.;Elizabeth A V Jones.;Jan G Hengstler.;Ahmed Ghallab.;Colinda L G J Scheele.;Frederik Nevens.;Hannelie Korf.;Guy Boeckxstaens.;Schalk Willem Van der Merwe.
来源: Gut. 2025年
Bacterial translocation in cirrhosis can trigger infection and hepatic decompensation, leading to systemic inflammation, organ failure and increased mortality. These infections often originate from the gastrointestinal tract after bacteria breach the intestinal barrier and disseminate to systemic sites.
4. Evaluating NGS variant callers in a challenging genomic context with a focus on the PRSS1-PRSS2 locus for hereditary pancreatitis.
作者: Yasir Kusay.;Denghao Wu.;Sunita Mc De Sousa.;Christopher J Drogemuller.;P Toby Coates.;Chung Hoow Kok.;Hamish S Scott.
来源: Gut. 2025年 8. Gut microbiome in IBD: past, present and the future.
IBD has become a global disease in the 21st century that shifts through four epidemiological stages. Alterations in the gut microbiome consisting of a complex multikingdom community of bacteria, fungi and viruses are strongly linked to disease pathogenesis. Advances in sequencing technologies, multiomics integration and experimental approaches have shed new insights into host-microbiota interactions in IBD and characterised mechanisms through which the microbiota and its metabolites contribute to disease. We review the evolution of microbiome-based research, with a focus on genetic and environmental factors affecting the gut microbiota, the role of cross-kingdom microbiome and their bioproducts in disease development and new strategies by which microbiome-based approaches can be used to diagnose, monitor, prevent and treat IBD.
12. Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach.
作者: Ram Prasad.;Yvonne Adu-Rutledge.;Borhane Ziani.;Jason L Floyd.;Edgar L Ready.;Sarbodeep Paul.;Fadeela Sheini.;Rati Sharma.;Robert F Rosencrans.;Sergio Li Calzi.;Micheli Severo Sielski.;Nicholas G Medawar.;Roshan Dutta.;Emory Brennis Johnson.;Xiaoping Qi.;Mohit Bansal.;Regina Lamendella.;Justin R Wright.;Suresh Kumar Verma.;Michael E Boulton.;Bruce R Stevens.;Craig W Vander Kooi.;Ramon C Sun.;Gavin Y Oudit.;Qiuhong Li.;Maria B Grant.
来源: Gut. 2025年
Both host and microbe metabolism of tryptophan (Trp) is altered in diabetes; however, the molecular mechanisms are incompletely understood.
13. Engineered virus-hunter vaccine overcomes HBV immune tolerance.
作者: Xiaoqing Chen.;Xue Liu.;Tao Xu.;Yalin Wang.;Peng Wang.;Han Liu.;Yichao Jiang.;Xiaojing Qin.;Liang Zhang.;Yueting Xiong.;Jiancheng Ding.;Yuanzhi Chen.;Fentian Chen.;Wenjing Ning.;Hongye Zeng.;Shiting Yang.;Lin Xu.;Tianying Zhang.;Quan Yuan.;Chao Liu.;Wenxin Luo.;Ningshao Xia.
来源: Gut. 2025年
Globally, an estimated 296 million individuals live with chronic hepatitis B virus (HBV) infection, carrying substantial risks of liver fibrosis, cirrhosis and hepatocellular carcinoma. Fewer than 20% of patients receiving nucleos(t)ide analogues or interferons achieve a functional cure, underscoring the urgent need for novel therapeutic strategies to improve clinical outcomes in patients with chronic HBV infection.
14. HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).
作者: Edo J Dongelmans.;Lesley A Patmore.;Seng Gee Lim.;Marc Bourliere.;Shaowen Jiang.;Nathalie Ganne-Carrie.;Willem-Pieter Brouwer.;Jordan J Feld.;Yuxian Huang.;Jose A Carrion.;Teresa Broquetas.;Qiankun Hu.;Scott Fung.;Fabrice Carrat.;Fabien Zoulim.;Bettina E Hansen.;Qing Xie.;Harry L A Janssen.;Milan J Sonneveld.
来源: Gut. 2025年
Peg-interferon (peg-IFN) plays an increasingly important role in HBV cure strategies, either in combination with novel antivirals, as a lead-in or as consolidation treatment.
15. Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study.
作者: Jun Fang.;Siyi Zhong.;Tielong Wang.;Kang He.;Aibo Mu.;Meiching Ong.;Yimou Lin.;Zebin Zhu.;Ning Wang.;Jiancheng Wu.;Zhihao Wang.;Zhao Li.;Feng Gao.;Li Zhuang.;Zhiyong Guo.;Shusen Zheng.;Hao Li.;Shugeng Zhang.;Qi Ling.
来源: Gut. 2025年
Immune checkpoint inhibitors (ICIs) enable successful hepatocellular carcinoma (HCC) downstaging or bridging for liver transplantation (LT) but increase allograft rejection risk. Although immune-related adverse events (irAEs) reflect immune activation during ICI therapy, their association with post-transplant rejection remains unclear.
16. A20-mediated KEAP1 ubiquitination orchestrates hepatocyte ferroptosis to ameliorate autoimmune hepatitis.
作者: Yu Chen.;Wanneng Li.;Shuhui Wang.;Han Wang.;Jiaxin Xu.;Meiping Yu.;Lijia Wang.;Zhenghao Ye.;Xinmei Yan.;Zhuoying Lin.;Ping Han.;Fang Xiao.;Wei Yan.;Dean Tian.;Yu Lei.;Mei Liu.
来源: Gut. 2025年
Autoimmune hepatitis (AIH) is characterised by death of hepatocytes and chronic inflammation. Patients with deleterious variants in A20 are identified with AIH presentations and immune activation. However, it remains unclear how A20 dysregulation contributes to AIH pathogenesis.
17. Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study.
作者: Patrick T F Kennedy.;Scott Fung.;Maria Buti.;Gurdal Yilmaz.;Wan-Long Chuang.;Tarik Asselah.;Masayuki Kurosaki.;John Jezorwski.;Vladislav Klyashtornyy.;Thierry Verbinnen.;Thomas Naoki Kakuda.;Oliver Lenz.;Carine Guinard-Azadian.;Michael Biermer.
来源: Gut. 2025年
In the hepatitis B e antigen positive (HBeAg+) chronic infection disease phase, approved treatments have limited effects on hepatitis B surface antigen (HBsAg) and HBeAg.
18. Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy.
作者: Taotao Sheng.;Raghav Sundar.;Supriya Srivastava.;Xuewen Ong.;Su Ting Tay.;Haoran Ma.;Tomoyuki Uchihara.;Benedict Shi Xiang Lian.;Takeshi Hagihara.;Mei Suen Kong.;Chang Xu.;Shamaine Wei Ting Ho.;Kie Kyon Huang.;Angie Lay Keng Tan.;Michelle Shu Wen Ng.;Jiamin Toh.;Clara Shi Ya Ng.;Vincenzo Nasca.;Chiara Carlotta Pircher.;Giovanni Randon.;Silvia Giordano.;Simona Corso.;Jeffrey Huey Yew Lum.;Joseph J Zhao.;Ming Teh.;Jimmy Bok Yan So.;Giovanna Sabella.;Shyam Prabhakar.;Jeeyun Lee.;Matthew Chau Hsien Ng.;Kohei Shitara.;Jessica Gasparello.;Matteo Fassan.;Filippo Pietrantonio.;Patrick Tan.
来源: Gut. 2025年
Human epidermal growth factor receptor 2 (HER2; ERBB2) is overexpressed or amplified in 15-20% of gastric cancers (HER2+ GC). Within individual HER2+ GCs, HER2/ERBB2 expression is often variable. Although HER2 therapeutic targeting improves outcomes for HER2+ GC patients, acquired resistance is frequent.
19. Pharmacological trials of early intervention in predicted severe acute pancreatitis: implications for therapeutic window and core outcome set.
作者: Juan Lin.;Wenhao Cai.;Arjun Kattakayam.;Wenhua He.;Lu Ke.;Peter Szatmary.;Tingting Liu.;Vikesh Singh.;Rajarshi Mukherjee.;Wei Huang.;Robert Sutton.
来源: Gut. 2025年 |